A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy

Status
Active
Cancer Type
Non-Hodgkin Lymphoma
Trial Phase
Phase III
Eligibility
18 and over, Male and Female
Study Type
Supportive care
NCD ID
NCT01361607
Protocol IDs
GWCA0962 (primary)
2009-016065-29
Study Sponsor
GW Pharmaceuticals

Summary

This nine week study will aim to determine the efficacy, safety and tolerability of Sativex® as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in patients with advance cancer.

Eligible patients will not be required to stop any of their current treatments or medications.